Due to the mandatory regulations of the American Food & Drug Administration (FDA), many Life Sciences companies are forced to professionalize their Maintenance & Asset Management. Since VDMXL specifically devotes attention to Safety, Health, Environment & Quality (SHEQ) Control, our methodology is used by various large pharmaceutical companies as their Maintenance & Asset Management model.
In addition to complying with laws and regulations, many Life Sciences companies also struggle with the competitive position of their production sites. Most definitely when faced with expiring patents. With VDMXL, we demonstrate how the Maintenance & Asset Management organization can maximize its contribution to the plant’s competitive position. Is there a requirement to reduce costs or increase uptime? Is there a requirement to reduce the inventory of spare parts or extend the assets’ lifetime? Which strategy creates the greatest economic value for the company; and even more important, how should the Maintenance & Asset Management organization be changed to achieve this? VDMXL helps address all of these issues, from strategy to implementation.
The result of the studies is a reduction of 100 hours in unscheduled downtime.
Maintenance has the potential to contribute a great deal of value to GSK’s operating results.
Each plant is compared in terms of the qualitative and quantitative benchmark data.
The improvement potential identified using VDMXL has since exceeded € 10 million per year.
Elaboration of a Maintenance & Asset Management roadmap for the coming 2 years